VivoSim LabsFRA:4OR 39 Graham Number is €7.74 as of Dec. 2025, which is 100% below its 10-year median of 0.38. GuruFocus rates FRA:4OR with a GF Score™ of 39/100 and a GF Value™ of €8.62. The stock has 4 warning signs investors should review. Among 254 Biotechnology companies, VivoSim Labs ranks better than 98.82% on this metric.
Graham Number is a figure that measures a stock's fundamental value by taking into account the company's earnings per share and book value per share. The Graham number is the upper bound of the price range that a defensive investor should pay for the stock. According to the theory, any stock price below the Graham number is considered undervalued, and thus worth investing in.
As of today (2026-07-01), the stock price of VivoSim Labs is €3.492. VivoSim Labs's graham number for the quarter that ended in Dec. 2025 was €7.74. Therefore, VivoSim Labs's Price to Graham Number ratio for today is 0.45.
The historical rank and industry rank for VivoSim Labs's Graham Number or its related term are showing as below:
FRA:4OR'
s Price-to-Graham-Number Range Over the Past 10 Years
Min: 0.13 Med: 0.38 Max: 0.53
Current: 0.13
During the past 13 years, the highest Price to Graham Number ratio of VivoSim Labs was 0.53. The lowest was 0.13. And the median was 0.38.
FRA:4OR's Price-to-Graham-Number is ranked better than 98.82% of 254
companies
in the Biotechnology industry
Industry Median: 1.735
vs FRA:4OR: 0.13
Graham Number is a combination of asset valuation and earnings power valuation. It is a very conservative way of valuing a stock.
VivoSim Labs (FRA:4OR) Graham Number Explanation
Ben Graham actually did not publish a formula like this. But he wrote in The Intelligent Investor (1948 version) regarding to the criteria for purchases:
Current price should not be more than 15 times average earnings of the past three years.
Current price should not be more than 1.5 times the book value last reported. However, a multiplier of earnings below 15 could justify a correspondingly higher multiplier of assets. As a rule of thumb we suggest that the product of the multiplier times the ratio of price to book value should not exceed 22.5. (This figure corresponds to 15 times earnings and 1.5 times book value. It would admit an issue selling at only 9 times earnings and 2.5 times asset value, etc.)
Unlike valuation methods such as DCF or Discounted Earnings, the Graham number does not take growth into the valuation. Unlike the valuation methods based on book value alone, it takes into account the earnings power. Therefore, the Graham Number is a combination of asset valuation and earnings power valuation.
In general, the Graham number is a very conservative way of valuing a stock. It cannot be applied to companies with negative book values.
VivoSim Labs's Price to Graham number Ratio for today is calculated as
Price to Graham number
=
Share Price (Today)
/
Graham number (Q: Dec. 2025 )
=
3.492
/
7.74
=
0.45
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Please keep these in mind:
1. Graham Number does not take growth into account. Therefore it underestimates the values of the companies that have good earnings growth. We feel that if the earnings per share grows more than 10% a year, Graham Number underestimates the value.
2. Graham Number punishes the companies that have temporarily low earnings. Therefore, an average of earnings makes more sense in the calculation of Graham Number.
3. Graham Numbers underestimates companies that are light with book.
VivoSim Labs Graham Number Related Terms
VivoSim Labs Graham Number Historical Data
* Premium members only.
The historical data trend for VivoSim Labs's Graham Number can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:4OR vs SLXN, CDT, CLDI: Graham Number Comparison
For the Biotechnology subindustry, VivoSim Labs's Price-to-Graham-Number, along with its competitors' market caps and Price-to-Graham-Number data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
VivoSim Labs Price-to-Graham-Number vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, VivoSim Labs's Price-to-Graham-Number distribution charts can be found below:
* The bar in red indicates where VivoSim Labs's Price-to-Graham-Number falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
VivoSim Labs (FRA:4OR) has a Graham Number of €7.74 as of Dec. 2025. The Graham Number values a company based on its per-share earnings and book value. View historical data on VivoSim Labs and its competitors. This is 1937% above median its historical median of 0.38. Over the past decade, VivoSim Labs' Graham Number has ranged from 0.13 to 0.53. According to the industry distribution chart, VivoSim Labs ranks #3 out of 254 companies in the Biotechnology industry, placing it in the top 1.2%.
Is VivoSim Labs' Graham Number too high?
VivoSim Labs' current Graham Number of €7.74 is 1937% above median its 10-year median of 0.38. Over the past 10 years, this metric has ranged from a low of 0.13 to a high of 0.53. Based on the distribution chart, VivoSim Labs ranks #3 out of 254 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, VivoSim Labs has a GF Score™ of 39/100, reflecting its overall financial health beyond just this single metric.
How does VivoSim Labs' Graham Number compare to SLXN and CDT?
According to the Biotechnology industry distribution chart, VivoSim Labs ranks #3 out of 254 companies for Graham Number. This places VivoSim Labs in the top 1% of its industry — outperforming the majority of peers. The industry median Graham Number is 1.74. Historically, VivoSim Labs' own Graham Number has ranged from 0.13 to 0.53 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Graham Number for a Biotechnology company?
The median Graham Number among Biotechnology companies is 1.74, based on 254 companies in the industry. Companies in the top quartile (top 25%) have a Graham Number significantly above this median, while those in the bottom quartile fall well below. However, Graham Number should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Graham Number mean?
A high Graham Number can signal that a stock is expensive relative to its fundamentals. The Graham Number values a company based on its per-share earnings and book value. View historical data on VivoSim Labs and its competitors. For the Biotechnology industry, the median Graham Number is 1.74 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. VivoSim Labs's current Graham Number is €7.74, which is 1937% above median its own 10-year median of 0.38. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is VivoSim Labs stock overvalued right now?
VivoSim Labs (FRA:4OR) has a current Graham Number of €7.74. The stock's GF Value™ is €8.62, compared to a current price of €3.49 — trading 59.5% below its estimated fair value. The current Graham Number is €7.74, which is 1937% above median its 10-year median of 0.38. VivoSim Labs' overall GF Score™ is 39/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Graham Number calculated?
Graham Number is calculated from a company's financial statements. For VivoSim Labs (FRA:4OR), the current Graham Number is €7.74 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is VivoSim Labs (FRA:4OR) Overvalued in 2026?
Based on GuruFocus' analysis, VivoSim Labs stock appears to be undervalued.
The current stock price of €3.49 is trading 59.5% below its estimated GF Value™ of €8.62.
Key valuation signals for FRA:4OR:
Graham Number: €7.74 (1937% above median its 10-year median of 0.38)
GF Value™: €8.62 vs. price of €3.49 (59.5% below fair value)
No single metric tells the full story. See the FRA:4OR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
VivoSim Labs Inc formerly, Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases. It is now offering liver toxicology predictive screening and research services as well as working on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at all stages of drug development.
39GF Score
Get the complete analysis for FRA:4OR
Graham Number is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:4OR has been successfully added to your 
